ClinicalTrials.gg
CompletedNCT04760626ONWARDS 5Updated Aug 11, 2026Results posted

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

A Phase 3 interventional study of Insulin icodec and Insulin Glargine 100U/mL in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 311 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,085
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
2nd of 27
1,085 · median 84
Started
2021
with 4 others
Phase 3
9 of 27
none open now
Registered
14th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 14th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin icodec to different daily insulins in people with type 2 diabetes.

The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random.

The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.

Participants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App.

The study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will be planned to meet individual needs. At 6 clinic visits participants will have blood samples taken.

Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
  • Male or female.
  • Age above or equal to 18 years at the time of signing informed consent.
  • Diagnosed with T2D greater than or equal to 180 days prior to the day of screening.
  • above 7.0% (53 mmol/mol) as measured by central lab.
  • Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.
  • Stable daily dose(s) greater than or equal to 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regimen(s): a .Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose. b .Any metformin combination formulations greater than or equal to 1500 mg or maximum tolerated or effective dose. c. Any of the following non-insulin antidiabetic drug classes including combinations (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose):i). Sulfonylureas ii). Meglitinides (glinides) iii). DPP-4 inhibitors iv. SGLT2 inhibitors v). Thiazolidinediones vi). Alpha-glucosidase inhibitors vii). Oral combination products (for the allowed individual Oral Antidiabetic Drugs (OADs)) viii). Oral or injectable GLP-1-receptor agonists.
  • Intensification with insulin is indicated to achieve glycaemic target (4.4-7.2 mmol/L, 80-130 mg/dL) at the discretion of the treating investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial product(s) or related products.
  • Previous participation in this trial. Participation is defined as signed .
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method (adequate contraceptive measures as required by local regulation or practice).
  • Participation in any clinical trial of an approved or non-approved medicinal product within 30 days before screening. (Simultaneous participation in a trial with the primary objective of evaluating an approved or non-approved investigational medicinal product for prevention or treatment of COVID-19 disease or postinfectious conditions is allowed if the last dose of the investigational medicinal product has been received more than 30 days before screening)
  • Any disorder which in the investigator's opinion might jeopardise subject's safety.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,085 participants (actual)

Study arms

  • Experimental
    Insulin icodec with DoseGuide

    Participants randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their titration.

    Drug: Insulin icodec

  • Active comparator
    Once daily basal insulin analogues

    Participants randomised to basal insulin analogue injections once daily

    Drug: Insulin Glargine 100U/mL · Drug: Insulin Degludec · Drug: Insulin Glargine 300U/mL

Interventions

  • Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.

  • DrugInsulin Glargine 100U/mL

    Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

  • Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

  • DrugInsulin Glargine 300U/mL

    Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to week 52 is presented.

    Time frame: Baseline (week 0), week 52

Secondary outcomes

  1. Time From Baseline to Treatment Discontinuation or Intensification

    Time from baseline to treatment discontinuation or intensification from baseline (week 0) to week 52 is presented.

    Time frame: From baseline (week 0) to week 52

  2. Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction

    Change in DTSQs in total treatment satisfaction is presented. The DTSQs questionnaire was used to assess participants treatment satisfaction which contained 8 components (DTSQs Item 1-8 : how satisfied are you with your current treatment, how often have you felt that blood sugars have been unacceptably high, how often have you felt that blood sugars have been unacceptably low, how convenient have you been finding your treatment to be recently, how flexible have you been finding your treatment to be recently, how satisfied are you with your understanding of your diabetes, would you recommend treatment to someone else with your kind of diabetes, how satisfied would you be to continue with present form of treatment). The result presented is the treatment satisfaction summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Total scores for treatment satisfaction range from 0-36 with 0 being the lowest and 36 being the highest score in total treatment satisfaction.

    Time frame: Baseline (week 0), week 52

  3. Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance Domain

    Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance domain at week 52 is presented. The TRIM-D questionnaire was developed to capture the impact of diabetes treatment on patients' functioning and well-being. The questionnaire was used to measure the compliance between the treatment groups. The total TRIM-D compliance score is computed by summing across the items and then transforming to a 0-100 scale with higher score indicating better compliance.

    Time frame: At end of treatment (week 52)

  4. Number of Severe Hypoglycaemic Episodes (Level 3)

    Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

    Time frame: From baseline (week 0) to week 57

  5. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 Millimoles Per Liter [mmol/L] (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter)

    Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 millimoles per liter \[mmol/L\] (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.

    Time frame: From baseline (week 0) to week 57

  6. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

    Time frame: From baseline (week 0) to week 57

07

Results

Posted Aug 26, 2025

Participant flow

The trial was conducted at 182 sites in Canada, Germany, Greece, Hungary, Poland, Turkey and the United States.

Participant flow — Overall Study
MilestoneInsulin IcodecOnce Daily Basal Insulin Analogue
Started542543
Full analysis set (fas)542543
Safety analysis set (sas)542538
Completed497493
Not completed4550
Withdrew: Withdrawal by subject2420
Withdrew: Lost to follow-up1419
Withdrew: Physician decision35
Withdrew: Death36
Withdrew: Site closure10

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to week 52 is presented.

Time frame:
Baseline (week 0), week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage of HbA1cInsulin IcodecOnce Daily Basal Insulin Analogue
Change in Glycated Haemoglobin (HbA1c)-1.68 ± 0.09-1.31 ± 0.12
Statistical analysis
  • Insulin Icodec vs Once Daily Basal Insulin Analogue · ANCOVA · p = <0.0001 · Treatment difference: -0.38 · 95% CI -0.66 to -0.09
SecondaryTime From Baseline to Treatment Discontinuation or Intensification

Time from baseline to treatment discontinuation or intensification from baseline (week 0) to week 52 is presented.

Time frame:
From baseline (week 0) to week 52
Reported as:
Median · Weeks
Time From Baseline to Treatment Discontinuation or Intensification
WeeksInsulin IcodecOnce Daily Basal Insulin Analogue
Time From Baseline to Treatment Discontinuation or Intensification20.1 (0.0 to 51.0)13.9 (0.0 to 55.1)
SecondaryChange in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction

Change in DTSQs in total treatment satisfaction is presented. The DTSQs questionnaire was used to assess participants treatment satisfaction which contained 8 components (DTSQs Item 1-8 : how satisfied are you with your current treatment, how often have you felt that blood sugars have been unacceptably high, how often have you felt that blood sugars have been unacceptably low, how convenient have you been finding your treatment to be recently, how flexible have you been finding your treatment to be recently, how satisfied are you with your understanding of your diabetes, would you recommend treatment to someone else with your kind of diabetes, how satisfied would you be to continue with present form of treatment). The result presented is the treatment satisfaction summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Total scores for treatment satisfaction range from 0-36 with 0 being the lowest and 36 being the highest score in total treatment satisfaction.

Time frame:
Baseline (week 0), week 52
Reported as:
Least squares mean · Score on a scale
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction
Score on a scaleInsulin IcodecOnce Daily Basal Insulin Analogue
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction4.68 ± 0.253.90 ± 0.25
SecondaryTreatment Related Impact Measure for Diabetes (TRIM-D) Compliance Domain

Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance domain at week 52 is presented. The TRIM-D questionnaire was developed to capture the impact of diabetes treatment on patients' functioning and well-being. The questionnaire was used to measure the compliance between the treatment groups. The total TRIM-D compliance score is computed by summing across the items and then transforming to a 0-100 scale with higher score indicating better compliance.

Time frame:
At end of treatment (week 52)
Reported as:
Least squares mean · Score on a scale
Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance Domain
Score on a scaleInsulin IcodecOnce Daily Basal Insulin Analogue
Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance Domain90.42 ± 0.6487.37 ± 0.64
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

Time frame:
From baseline (week 0) to week 57
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecOnce Daily Basal Insulin Analogue
Number of Severe Hypoglycaemic Episodes (Level 3)05
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 Millimoles Per Liter [mmol/L] (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter)

Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 millimoles per liter \[mmol/L\] (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.

Time frame:
From baseline (week 0) to week 57
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 Millimoles Per Liter [mmol/L] (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter)
EpisodesInsulin IcodecOnce Daily Basal Insulin Analogue
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 Millimoles Per Liter [mmol/L] (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter)10476
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

Time frame:
From baseline (week 0) to week 57
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecOnce Daily Basal Insulin Analogue
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)10481

Adverse events

Collected over From baseline week 0 to week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Icodec3/542 (0.6%)45/542 (8.3%)43/542 (7.9%)
Once Daily Basal Insulin Analogue6/543 (1.1%)57/538 (10.6%)55/538 (10.2%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventInsulin IcodecOnce Daily Basal Insulin Analogue
Coronary artery diseaseCardiac disorders2/5425/538
Acute myocardial infarctionCardiac disorders4/5421/538
Acute kidney injuryRenal and urinary disorders0/5423/538
COVID-19 pneumoniaInfections and infestations2/5423/538
COVID-19Infections and infestations3/5420/538
Cardiac failureCardiac disorders3/5420/538
Ankle fractureInjury, poisoning and procedural complications0/5422/538
Cardiac arrestCardiac disorders0/5422/538
DeathGeneral disorders0/5422/538
HypoglycaemiaMetabolism and nutrition disorders0/5422/538
Most frequent other events
Most frequent other events
EventInsulin IcodecOnce Daily Basal Insulin Analogue
COVID-19Infections and infestations43/54255/538

Baseline characteristics

Full analysis set included all randomised participants.

Age, Continuous
Age, Continuous(Years)Insulin IcodecOnce Daily Basal Insulin AnalogueTotal
Mean59.15 ± 10.7959.39 ± 10.1559.27 ± 10.47
Sex: Female, Male
Sex: Female, Male(Participants)Insulin IcodecOnce Daily Basal Insulin AnalogueTotal
Female233230463
Male309313622
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin IcodecOnce Daily Basal Insulin AnalogueTotal
Hispanic or Latino514495
Not Hispanic or Latino490499989
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Insulin IcodecOnce Daily Basal Insulin AnalogueTotal
American Indian Or Alaska Native213
Asian281947
Black Or African American242852
Native Hawaiian Or Other Pacific Islander213
Not Reported101
White478493971
Other718
08

Study locations

311 sites
  • Univ of Alabama Birmingham
    Birmingham, Alabama 35233, United States
  • Lakeview Clinical Research, LLC
    Guntersville, Alabama 35976, United States
  • Pri Med Grp dba/Gil Ctr Fam
    Gilbert, Arizona 85296, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Advanced Clinical Research/Rancho Paseo Medical Group
    Banning, California 92220, United States
  • American Clinical Trials
    Buena Park, California 90620, United States
  • San Fernando Valley Hlth Inst, LLC
    Canoga Park, California 91304, United States
  • Med Center Medical Clinic
    Carmichael, California 95608, United States
  • Headlands Research California, LLC
    Escondido, California 92025, United States
  • Valley Research
    Fresno, California 93720, United States
  • Advanced Investigative Medicine, Inc.
    Hawthorne, California 90250, United States
  • Diabetes/Lipid Mgmt & Res Ctr
    Huntington Beach, California 92648, United States
  • Altman Clin & Trans Res Inst
    La Jolla, California 92037, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California 92037, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • Torrance Clin Res Inst, Inc.
    Lomita, California 90717, United States
  • Adventist Health White Memorial
    Los Angeles, California 90033, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • Clinical Trials Research_Sacramento
    Sacramento, California 95821, United States
  • San Diego Family Care
    San Diego, California 92111, United States
  • NorCal Endocrinology and Internal Medicine
    San Ramon, California 94583, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • Handelsman Yehuda
    Tarzana, California 91356-3551, United States
  • Diabetes Research Center
    Tustin, California 92780, United States
  • Coastal Metabolic Research Center
    Ventura, California 93003, United States
  • Denver Endocrinology Diabetes and Thyroid Center
    Englewood, Colorado 80113, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • MedStar Diabetes Institute
    Washington D.C., District of Columbia 20010, United States
  • Clinical Res Of W Florida Inc
    Clearwater, Florida 33765, United States
  • Revival Research
    Doral, Florida 33122, United States
  • Est Cst Inst for Rsrch,Jksnvil
    Jacksonville, Florida 32216, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • University Of Miami
    Miami, Florida 33136, United States
  • Adult Medicine of Lake County, Inc
    Mt. Dora, Florida 32757, United States
  • Suncoast Clin Res Port Richey
    New Port Richey, Florida 34652, United States
  • Florida Institute for Clinical research
    Orlando, Florida 32825, United States
  • Palm Harbor Medical Associates
    Palm Harbor, Florida 34684-3609, United States
  • Suncoast Clinical Research, Inc.
    Palm Harbor, Florida 34684, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • Clinical Research of Cent FL
    Winter Haven, Florida 33880, United States
  • Emory University SOM
    Atlanta, Georgia 30303, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Physicians Research Assoc. LLC
    Lawrenceville, Georgia 30046, United States
  • Endo Res Solutions Inc
    Roswell, Georgia 30076, United States
  • Endo Res Solutions, Inc
    Roswell, Georgia 30076, United States
  • RNA America Health Sciences
    Sugar Hill, Georgia 30518, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Central Illinois Diabetes and Clinical Research
    Springfield, Illinois 62711, United States
  • American Health Network of Indiana, LLC_Avon_0
    Avon, Indiana 46123, United States
  • Clinical Research Advantage, Inc.-Evansville
    Evansville, Indiana 47714, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • St Elizabeth Physicians Heart
    Covington, Kentucky 41011, United States
  • Four Rivers Clinical Research Inc
    Paducah, Kentucky 42001, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • MedStar Community Clin Res Ctr
    Hyattsville, Maryland 20782, United States
  • Endo and Metab Consultants
    Rockville, Maryland 20852, United States
  • MassResearch, LLC_Waltham
    Waltham, Massachusetts 02453, United States
  • Northern Pines Hlth Ctr, PC
    Buckley, Michigan 49620, United States
  • Arcturus Healthcare, PLC.
    Troy, Michigan 48098, United States
  • Diabetes & Endo Specialists Inc
    Chesterfield, Missouri 63017, United States
  • Jefferson City Medical Group, PC
    Jefferson City, Missouri 65109, United States
  • St Johns Health System
    Springfield, Missouri 65807-7304, United States
  • Rocky Mountain Health Network
    Billings, Montana 59102, United States
  • Methodist Physicians Clin
    Omaha, Nebraska 68114, United States
  • Univ of Nebraska Medical CTR
    Omaha, Nebraska 68198-3020, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89148, United States
  • Southern New Hampshire Diabetes and Endocrinology
    Nashua, New Hampshire 03060, United States
  • Southern New Hampshire Diabete
    Nashua, New Hampshire 03060, United States
  • Albuquerque Clin Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • N.Y. Total Medical Care PC
    Brooklyn, New York 11215, United States
  • Northwell Health Div of Endo
    Great Neck, New York 11021, United States
  • Mid Hudson Medical Research, PLLC
    New Windsor, New York 12553, United States
  • CTSI Research Center
    New York, New York 10016, United States
  • Endocrine Associates of Long Island, PC
    Smithtown, New York 11787, United States
  • Staten Island Diabetes
    Staten Island, New York 10301-3914, United States
  • SUNY Upstate Medical University_Syracuse_0
    Syracuse, New York 13131, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • PMG Research of Charlotte
    Charlotte, North Carolina 28209, United States
  • Physicians East Endocrinology
    Greenville, North Carolina 27834, United States
  • Medication Management, LLC
    Raleigh, North Carolina 27609, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Ardmore Family Practice_Winston Salem
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Plains Clinical Research Center, LLC_Fargo
    Fargo, North Dakota 58104, United States
  • Diab & Endo Assoc of Stark Co
    Canton, Ohio 44718, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43203, United States
  • Providence Health Partners Ctr
    Dayton, Ohio 45439, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Your Diabetes Endocrine Nutrition Group, Inc.
    Mentor, Ohio 44060, United States
  • Clinical Research Source Inc
    Perrysburg, Ohio 43551, United States
  • New Venture Medical Research
    Wadsworth, Ohio 44281, United States

Showing the first 100 of 311 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Philis-Tsimikas A, Bajaj HS, Begtrup K, Cailleteau R, Gowda A, Lingvay I, Mathieu C, Russell-Jones D, Rosenstock J. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2023 Feb;25(2):331-341. doi: 10.1111/dom.14871. Epub 2022 Oct 14. PubMed 36106652 ↗
  • Philis-Tsimikas A, Krogsdahl Bache J, Fu A, Kellerer M, Salvesen-Sykes K, Bain SC. Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec. Diabetes Ther. 2025 Aug;16(8):1615-1631. doi: 10.1007/s13300-025-01745-4. Epub 2025 Jun 4. PubMed 40465144 ↗
  • Riddell MC, Heller S, Carstensen L, Rocha TMP, Kehlet Watt S, Woo VC. The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5. Diabetologia. 2025 Jul;68(7):1416-1422. doi: 10.1007/s00125-025-06414-6. Epub 2025 Apr 5. PubMed 40186685 ↗
  • Billings LK, Asong M, Bog M, Clancy S, Kruse C, de Laguiche E, Maddaloni E. AUGMENTed Real-World Data Enhances Comparative Efficacy Between Once-Weekly Insulin Icodec with Dosing Guide App Versus Once-Daily Insulin Glargine U300 in Insulin-Naive Type 2 Diabetes. Diabetes Ther. 2025 Feb;16(2):227-239. doi: 10.1007/s13300-024-01679-3. Epub 2024 Dec 19. PubMed 39699848 ↗
  • Polonsky W, Benamar M, Carstensen L, Davies M, Meller Donatsky A, Franek E, Kellerer M, Philis-Tsimikas A, Goldenberg R. Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1. Diabetes Res Clin Pract. 2024 Nov;217:111885. doi: 10.1016/j.diabres.2024.111885. Epub 2024 Oct 4. PubMed 39368488 ↗
  • Bajaj HS, Aberle J, Davies M, Donatsky AM, Frederiksen M, Yavuz DG, Gowda A, Lingvay I, Bode B. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Ann Intern Med. 2023 Nov;176(11):1476-1485. doi: 10.7326/M23-1288. Epub 2023 Sep 26. PubMed 37748181 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2022, 17 months.

Results were first posted in Aug 2025, 3 years after primary completion. A results delay was requested in Aug 2023.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2021
First posted
Feb 18, 2021
StartActual
Mar 1, 2021
Primary completionActual
Aug 12, 2022
CompletionActual
Aug 29, 2022
Results delay requested
Aug 10, 2023
Results first posted
Aug 26, 2025
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04760626
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 18, 2021
Start date
Mar 1, 2021
Primary completion
Aug 12, 2022
Completion
Aug 29, 2022
Results posted
Aug 26, 2025
Last update
Aug 11, 2026

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion